In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 25 of 434

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510	Technology appraisal guidance	26 August 2026
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]	Technology appraisal guidance	TBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]	Technology appraisal guidance	22 April 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance	TBC
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy [ID6354]	Technology appraisal guidance	14 January 2026
Advanced breast cancer: diagnosis and management (Partial update)	NICE guideline	TBC
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575	Technology appraisal guidance	TBC
Aggressive behaviour in people receiving NHS or social care: prevention and management	NICE guideline	28 January 2027
AI software for electroencephalogram (EEG) interpretation in epilepsy	Health technology evaluation	TBC
Alcohol Use Disorders (update)	NICE guideline	TBC
Algorithms applied to spirometry to support the diagnosis of lung conditions in primary care and community diagnostic centres	Health technology evaluation	2 April 2026
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]	Technology appraisal guidance	TBC
ALXN1840 for treating Wilson disease [ID6422]	Technology appraisal guidance	TBC
Alzheimer's disease (early) - gantenerumab [ID6142]	Technology appraisal guidance	TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	TBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]	Technology appraisal guidance	11 February 2026
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance	TBC
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value Assessment	Health technology evaluation	19 May 2026
Artificial intelligence software to help detect and characterise colorectal polyps	Diagnostics guidance	TBC
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]	Technology appraisal guidance	TBC
Asunercept for treating glioblastoma [1301]	Technology appraisal guidance	TBC

Results per page

10
25
50
All